RevvityRVTY
Recorded

Revvity Investor Day 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration2 hr 50 min

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Good morning, and welcome to Revvity's 2026 Investor Day. I'm Steve Willoughby, Head of Investor Relations for the company. It's great that so many of you could join us in person today, and all of you who are joining us online virtually. I think we've got a great day planned for you. First, a few disclosures. As you can imagine, we're going to be making some assumptions and estimates today in the presentations. You should only rely upon these estimates as of today, as they may change in the future. I'd also point you to our disclosures in our recent press releases, SEC filings, website, as well as those on the screen behind me. In today's presentation, the projections and estimates made are based on the guidance we provided first last week on Tuesday, November 3rd. As a reminder, this guidance excludes our China immunodiagnostics business as well.

Speaker

I think we've got a great day planned for you today. First, Prahlad, our CEO, is going to come up, talk to you about the progress we've been making over the last few years, who Revvity is today, and where we're going in the future. Next, Kevin, who leads our Signals software business, will share the progress we've been making in Signals. We'll touch on some of the new products we've launched this year and what that means for the future. Following that, I'm going to bring the scientists up on stage, David and Craig, two lifetime career scientists, PhDs, who lead some of our key businesses. David and Craig are going to spend some time talking to you about how we believe science is changing because of AI and where Revvity fits within that and its potential. At that point, we'll do about 20 minutes of Q&A.

Speaker

We'll take a 15-minute break. Coming back from the break, Max, our CFO, will come up, talk to you about the operational, commercial, and financial progress we've been making over the last few years, and why we believe we are set up so well financially for the future. We'll then do another Q&A session. At that point, the presentations will conclude, and for those of you who are here in person, we're going to break up into small groups and do some product demos. So overall, I think it's going to be a great day. I hope you come away with it learning more about Revvity and where we're going in the future, but also how we see science changing because of AI and why that's so exciting for the company. With that, I'll now like to turn it over to Prahlad Singh, our President and CEO. Prahlad. After you. Good morning, and I'm glad you're here today.

Speaker

Despite all the Microsoft Outlook challenges and the weather challenges, I'm grateful for you to be here in person. Sometimes I take umbrage to Steve Willoughby not giving my PhD any value, and he keeps talking about the other two as having PhD. But I'm excited for you being here today, and I'm excited for you to hear from my colleagues, who in a bit, I think, will share some interesting thoughts about the future. Before we spend time on where science is going and the opportunities we see ahead, I want to start by grounding you into Revvity, the portfolio that we've built, why the transformation we've gone through over the last few years, the markets we serve, and the strengths we have that we think position us very well for the next chapter. Our purpose should be our starting point.

Speaker

Revvity exists to expand the boundaries of human potential through science. We are a science-driven company whose mission has always been to turn innovation into meaningful improvements in human health. Revvity is a differentiated life sciences and diagnostics company built around specialized and scientifically demanding end markets. Diagnostics provides a durable foundation with strong positions in clinical areas where innovation and expertise matter. Life sciences combines reagents, instruments, and software to help researchers generate richer evidence and better scientific outcomes. Our growing ability to connect these critical workflows around data, context, technologies, and decisions make it more valuable for our customers' critical workflows. Together, these capabilities position Revvity to advance scientific discovery and improve human health. When we created Revvity, and some of you have been part of this journey, we were very intentional about the type of company and the quality of revenue base we wanted to build.

Speaker

Higher quality, more resilient revenue base with meaningful scale across life sciences and diagnostics. Approximately 85% of our revenue is recurring in nature, providing a durable foundation through consumables, reagents, assays, and software embedded in ongoing customer activity. The balance between life sciences and diagnostics is a strength. Diagnostics provides durable, recurring demand, while life sciences provides exposure to scientific innovation and discovery with different underlying demand drivers. Most importantly, the last several years have demonstrated the resilience and differentiation that this intentional portfolio was designed to create, with 10,000 employees globally and a diverse revenue base. Starting with diagnostics, it's a highly differentiated $1.4 billion franchise that's focused on specialized areas where scientific expertise and innovation make a lot of difference.

Speaker

As you heard on our earnings call, diagnostic continues to perform very well, delivering mid-single-digit organic growth in the third quarter and demonstrating the durability of this business across different market environments. We compete with complete screening solutions, bringing together assays, instruments, software, and automation around the needs of our diagnostic customers. Immunodiagnostics and reproductive health are complementary growth engines with opportunity for menu expansion, automation, increased adoption, and geographic expansion. 90% of our revenue in diagnostics is recurring in nature. However, this is not a static franchise. We continue to innovate around menu automation and workflow while expanding geographically and increasing adoption across our specialized end markets. Taking a deeper look into the immunodiagnostic side of the portfolio, it is an $800 million specialized diagnostics franchise that's led by a strong global position in autoimmune, complemented by infectious disease and allergy.

Speaker

Esoteric autoimmune testing today is an attractive but still under-penetrated area of medicine, where Revvity differentiates through scientific expertise and a broad specialized testing menu. The portfolio has significant geographic runway, particularly in the U.S., where our presence, while materially it has grown, it is still under-indexed relative to the size of the market. Continued menu adoption and greater automation are central to widening our competitive advantage and opening more customer workflows. In infectious diseases, we are in stronger growing markets such as latent TB testing, where we are continuing to work to bring in additional novel solutions to the market, with additional automation expected in 2027. Looking a bit deeper into the portfolio, the differentiation in immunodiagnostics comes from combining the specialized assay content with the automation and workflows that laboratories need to put that science into practice.

Speaker

Autoimmune is the clearest example where complex diseases require the breadth and depth of testing, and our comprehensive menu allows laboratories to move from broad screening towards increasingly disease-specific answers. Automation is continuing to become more and more important here, and the same model extends across infectious diseases and allergies, pairing differentiated assays with workflow capabilities tailored to our customers' needs. Looking at reproductive health now, Revvity has built a number one position in newborn screening over more than 40 years, supported by deeply established relationships with public health programs around the world. The growth opportunity for us here is much bigger than birth rates. There are nearly 100 million newborns today that still go untested, leaving substantial runway for geographic expansion. Existing screening programs also continue to expand the number of conditions that they test for, creating growth through greater menu expansion.

Speaker

As therapies emerge for more rare diseases, earlier identification becomes increasingly valuable, creating new opportunities for screening and strengthening the relevance of our installed base. This is both an attractive business and a direct expression of our purpose, which is helping identify serious conditions earlier and giving more newborns the opportunity to a healthier start to life. Let's take a little deeper look into the portfolio on reproductive health. It extends well beyond a single test or a platform, spanning newborn screening, maternal and fetal health, cord blood banking, and multiomics. Newborn screening, however, remains the foundation of embedded expertise and customer relationships that we bring from sample to result workflow. The breadth of our portfolio gives us multiple ways to serve families and healthcare systems across reproductive and pediatric health, rather than relying on one singular modality.

Speaker

Genomics and multiomics extends that foundations into new forms of screening and insight, with Genomics England partnership demonstrating how our existing capabilities can support increasingly sophisticated genomic workflow. The opportunity for us here is to keep leveraging the installed screening infrastructure that we have, the scientific expertise and workflows that we bring, as new technologies and new screening applications emerge. Overall, we've built a strong position in specialty diagnostics by delivering the quality and reliability our customers depend on every day. The opportunity for us here now is to build on these positions through continued innovation. Over the next couple of slides, I'll give you a few examples of how we are bringing this to life across our portfolio. Starting on the immunodiagnostic side, nephrology is a good example of where we see specialty diagnostics going next.

Speaker

Chronic kidney disease today remains significantly underdiagnosed, and the way the disease is understood is increasingly moving beyond looking at the morphology towards a more molecular view of what is driving it. Our existing portfolio today includes an array of IVD tests in areas such as primary membranous nephropathy and kidney function, spanning multiple testing technologies, as you can see up there. However, newer biomarkers such as PLA2R and anti-nephrin may help provide additional insight into immune-related damage to the kidney, both to the filters and also inflammation that is being caused that are associated with the kidney disease, rather than looking at the morphology alone. Nephrology and even neuroimmunology are examples of specialty areas where proprietary biological content and scientific expertise can matter, and that expands beyond this opportunity. Looking at this now at newborn screening.

Speaker

Our focus really is how do we shape the next evolution of newborn screening, building on the longstanding relationship that we have in this domain. Next-gen sequencing should be a complementary test to traditional newborn screening and not looked upon as a replacement for it. Sequencing can broaden the range of genetic conditions that can be assessed, while existing biochemical and immunoassay approaches continue to play an important screening and confirmatory role, with the key advantage being affordability. Revvity's differentiation is the ability to bring together the complete NGS workflow while configuring the solution around a customer's existing laboratory infrastructure. So, really, if you think of it, our ability is to bring both the traditional and genomic approaches together with complete screening workflows, positioning us as a continued leader in newborn screening as that modality evolves.

Speaker

To give you a couple of examples here, building on this relationship for us, as therapies emerge for more rare diseases and they become more actionable, earlier identification becomes increasingly valuable. Screening beyond newborns to identify at-risk patients who are older, but before symptoms appear. Type 1 diabetes is now a tangible proof of that strategy. We recently launched our GSP T1D 3plex kit CIVDR Multiplex Assay that is designed for population-scale screening to identify children at risk of developing type 1 diabetes before the symptoms appear. Building on this partnership of ours with Sanofi, we are developing an even broader assay with regulatory submissions planned across major markets and an expected launch in 2027. Our integrated portfolio here is a key differentiator. BioLegend's reagents, Euroimmun's automation and disease area expertise, Reproductive Health's commercial capabilities, and the global lab footprint that we bring together.

Speaker

Bringing life sciences and diagnostics together helps us bridge the gap from discovery to cure. Applying this across our portfolio of rare diseases, chronic diseases, and oncology being certain examples. I think we are skipping a slide here. Coming out of diagnostics, life sciences is an example of how we are bringing it from discovery, from care to continuum. The portfolio on life sciences spans across reagents, instruments, and software that help power scientific discovery. Our portfolio here has 85% of the revenue coming on a recurring basis. It is a $1.5 billion franchise with a $30 billion addressable market. We have had a consistent track record of innovation and integrated solutions that we have brought for our customers, from early discovery through drug development. Signals is an added layer that we have in addition to our reagents and instruments as part of that portfolio.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day